NCI Formalizes Role of Advocates

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 11 No 1
Volume 11
Issue 1

BETHESDA, Maryland-In what it calls "a landmark initiative," the National Cancer Institute has established a large network of cancer advocates to provide insights and feedback to its researchers and staff. The new group-Consumer

BETHESDA, Maryland—In what it calls "a landmark initiative," the National Cancer Institute has established a large network of cancer advocates to provide insights and feedback to its researchers and staff. The new group—Consumer Advocates in Research and Related Activities (CARRA)—replaces the informal manner in which the Institute had sought the views of patients and other outsiders. More than 200 advocates have been named to serve 3-year terms.

Recent Videos
The mechanism of CTO1681 may allow it to reduce the production of a broad range of proinflammatory cytokines in DLBCL.
Younger and fitter patients with relapsed/refractory multiple myeloma were more likely to receive bispecific antibodies in community oncology settings.
Mechanistic treatment benefits were observed in the phase 2 STEM trial for patients with multiple myeloma.
Data from a retrospective cohort study showed that one-fifth of patients with multiple myeloma received bispecific antibodies in rural community settings.
Being able to treat patients with cevostamab who have multiple myeloma after 1 to 3 prior lines of therapy vs 4 lines may allow for better outcomes.
Using the monitoring of symptoms and quality of life platform may provide a quick and efficient system for patients to submit outcome data.
2 experts are featured in this series.
With many treatments emerging in the EGFR-mutated lung cancer landscape, sequencing therapy has emerged as a key consideration for these patients.
Related Content